Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.50 USD
+0.01 (0.05%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $20.49 -0.01 (-0.05%) 4:48 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CPRX 20.50 +0.01(0.05%)
Will CPRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
Other News for CPRX
Catalyst Pharmaceuticals: High Valuation Amid Weak Long-Term Prospects (Rating Downgrade)
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE? in Japan
Dyne stock tumbles 31% amid drug updates, management changes
Insider Sale at Catalyst Pharmaceuticals Inc (CPRX): Chief Operating & Scientific Officer ...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences